Discontinuation of anti- @entity101 drugs increases 11-year XXXX risk in community-dwelling elderly (the Bambu   Cohort Study of Ageing).

@entity1 @entity101 @entity8404 @entity734 @entity65
BACKGROUND: @entity101 remains a major public health problem whose management is hampered by poor persistence with pharmacological therapy. The aim of this study was to evaluate the association between discontinuing @entity734 ( @entity734 ) and the risk of @entity65 in the elderly. METHODS: A population-based prospective cohort study of all of the >=  60-year-old residents in Bambu   city (Brazil) enrolled 1606 subjects (92.2%), of whom 1494 (93.0%) were included in this study. The use of @entity734 was ascertained annually in a real-clinical context, and time-varying @entity8404 exposure was categorised as non-use, current use or stopped. The predicted @entity65 rates were estimated using interval Poisson models for ungrouped @entity1 -time data, taking into account current levels of systolic blood pressure (BP). RESULTS: The overall adjusted @entity65 risk ratio of @entity8404 stoppers vs current users was 3.12 (95% CI: 2.35-4.15). There was a significant interaction with BP levels: the association between discontinuing @entity734 and the risk of @entity65 was stronger at higher systolic BP levels. The estimates of the risk of @entity65 over the follow-up period were similar in @entity8404 users and non-users, for whom @entity734 were never prescribed. CONCLUSION: Discontinuing @entity734 increases the risk of @entity65 in the elderly. Misconceptions about symptoms or drug-related adverse effects could underlie a subject's decision to discontinue @entity734 . Greater attention should be paid to the choice of @entity734 and informative action.
